{ "run": { "id": "cmnr14k37050rp658vtrkq09q", "region": "US", "assetId": "cmnr14iym050bp658hxxmbi97", "ticker": "MCK", "snapshotId": "cmnr14k2i050gp658t16dsnxb", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:22.865Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr14k2i050gp658t16dsnxb", "assetId": "cmnr14iym050bp658hxxmbi97", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 871.18, "dayLow": 852.33, "volume": 733211, "dayHigh": 873.83, "currency": "USD", "prevClose": 856.62, "week52Low": 637, "week52High": 999 }, "fundamentals": { "pe": 26.0243619489559, "beta": 0.491932024891068, "epsTTM": 25.86, "fcfTTM": 5505000000, "growth": { "epsYoy": 0.1472937000887312, "revenueYoy": -0.7043372668506702 }, "sector": "Wholesale-Drugs, Proprietaries & Druggists' Sundries", "margins": { "net": 0.01117202660185761, "gross": 0.03471240980425404, "operating": 0.01525085250287308 }, "website": "http://mckesson.com", "industry": "Healthcare", "pegRatio": 1.76683469376345, "ebitdaTTM": 5078000000, "forwardPe": 17.4214341185607, "marketCap": 62700000000, "totalCash": 5691000000, "totalDebt": 6845000000, "debtEquity": -3.30038572806172, "quickRatio": 0.5086358028699435, "revenueTTM": 106158000000, "companyName": "MCKESSON CORP", "priceToBook": 1.14176988534218, "currentRatio": 0.8992597883254334, "dividendYield": 0.0041054864624733, "returnOnAssets": 0.01578387010912962, "returnOnEquity": -1.58871745419479, "analystOpinions": null, "businessSummary": "McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company. The company is headquartered in Irving, Texas. It is a component of the S&P 500 and is listed on the New York Stock Exchange, where it is traded under the ticker symbol \"MCK\".", "enterpriseValue": 86892926000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 45000, "sharesOutstanding": 122487456, "enterpriseToEbitda": 17.11164356045687, "analystTargetMedian": null, "enterpriseToRevenue": 0.8185245200550123, "operatingCashflowTTM": 2734000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:22.842Z" }, "results": [ { "id": "cmnr14k3a050tp65897hh3ar1", "runId": "cmnr14k37050rp658vtrkq09q", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MCK\",\"currency\":\"USD\",\"current_price\":871.18,\"target_price_6m\":915,\"target_price_12m\":950,\"recommendation\":\"BUY\",\"confidence\":0.67,\"thesis_bullets\":[\"Dominant US pharma distributor with ~33% market share and defensive moat\",\"Aggressive buybacks shrink float, boosting EPS despite flat organic revenue\",\"FCF yield near 8.8% supports continued capital return and debt management\",\"Forward P/E of 17.4x suggests strong forward earnings growth trajectory\",\"GLP-1 and specialty pharma distribution offer secular volume tailwinds\"],\"key_drivers\":[{\"driver\":\"Specialty pharma and GLP-1 distribution volume growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Aggressive share repurchases compounding EPS growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"US Oncology network expansion and margin accretion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Revenue base reset post-divestitures stabilizes margin profile\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Low beta provides defensive portfolio characteristics\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Thin net margins (~1.1%) leave little room for cost overruns\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Negative stockholders equity limits balance sheet flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Drug pricing reform or rebate compression risk\",\"impact\":\"HIGH\",\"direction\":\"NEG\"}],\"risks\":[\"Federal drug pricing legislation could compress distribution margins\",\"Opioid litigation settlement obligations may resurface or increase\",\"Customer concentration risk if large pharmacy chains renegotiate terms\",\"Potential macro slowdown reducing elective healthcare utilization\",\"Current ratio below 1.0 indicates near-term liquidity tightness\"],\"assumptions\":{\"revenue_cagr_3y\":0.04,\"ebit_margin_target\":0.017,\"wacc\":0.085,\"terminal_multiple\":18.5},\"scenarios\":{\"bear\":{\"target_price\":750,\"prob\":0.2,\"notes\":\"Drug pricing reform hits margins; buyback pace slows on liquidity concerns.\"},\"base\":{\"target_price\":950,\"prob\":0.55,\"notes\":\"Steady EPS compounding via buybacks and specialty pharma growth at current multiples.\"},\"bull\":{\"target_price\":1080,\"prob\":0.25,\"notes\":\"GLP-1 volume surge plus margin expansion drives re-rating toward 52-week highs.\"}},\"method_notes\":\"Blended valuation: FCF yield (8.8% on $5.5B TTM FCF) and forward P/E (~17.4x) anchored to ~$50 forward EPS implying ~14% EPS CAGR from buybacks + organic. 12M target of $950 implies ~9% upside, consistent with BUY. Revenue YoY decline (-70%) reflects divestitures, not organic weakness. Negative equity from buybacks is structural, not distress. Sell-side targets noted but not used as inputs. Disclaimer: not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Federal drug pricing legislation could compress distribution margins", "Opioid litigation settlement obligations may resurface or increase", "Customer concentration risk if large pharmacy chains renegotiate terms", "Potential macro slowdown reducing elective healthcare utilization", "Current ratio below 1.0 indicates near-term liquidity tightness" ], "ticker": "MCK", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady EPS compounding via buybacks and specialty pharma growth at current multiples.", "target_price": 950 }, "bear": { "prob": 0.2, "notes": "Drug pricing reform hits margins; buyback pace slows on liquidity concerns.", "target_price": 750 }, "bull": { "prob": 0.25, "notes": "GLP-1 volume surge plus margin expansion drives re-rating toward 52-week highs.", "target_price": 1080 } }, "confidence": 0.67, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 18.5, "ebit_margin_target": 0.017 }, "key_drivers": [ { "driver": "Specialty pharma and GLP-1 distribution volume growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Aggressive share repurchases compounding EPS growth", "impact": "HIGH", "direction": "POS" }, { "driver": "US Oncology network expansion and margin accretion", "impact": "MED", "direction": "POS" }, { "driver": "Revenue base reset post-divestitures stabilizes margin profile", "impact": "MED", "direction": "POS" }, { "driver": "Low beta provides defensive portfolio characteristics", "impact": "LOW", "direction": "POS" }, { "driver": "Thin net margins (~1.1%) leave little room for cost overruns", "impact": "MED", "direction": "NEG" }, { "driver": "Negative stockholders equity limits balance sheet flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Drug pricing reform or rebate compression risk", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Blended valuation: FCF yield (8.8% on $5.5B TTM FCF) and forward P/E (~17.4x) anchored to ~$50 forward EPS implying ~14% EPS CAGR from buybacks + organic. 12M target of $950 implies ~9% upside, consistent with BUY. Revenue YoY decline (-70%) reflects divestitures, not organic weakness. Negative equity from buybacks is structural, not distress. Sell-side targets noted but not used as inputs. Disclaimer: not investment advice.", "current_price": 871.18, "recommendation": "BUY", "thesis_bullets": [ "Dominant US pharma distributor with ~33% market share and defensive moat", "Aggressive buybacks shrink float, boosting EPS despite flat organic revenue", "FCF yield near 8.8% supports continued capital return and debt management", "Forward P/E of 17.4x suggests strong forward earnings growth trajectory", "GLP-1 and specialty pharma distribution offer secular volume tailwinds" ], "target_price_6m": 915, "target_price_12m": 950 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 38335, "createdAt": "2026-04-09T05:21:22.865Z", "usage": { "inputTokens": 3664, "outputTokens": 1779, "costUsd": 0.062795 } }, { "id": "cmnr14k3a050wp6585y17tkvc", "runId": "cmnr14k37050rp658vtrkq09q", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Equity_Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"MCK\",\n \"currency\": \"USD\",\n \"current_price\": 871.18,\n \"target_price_6m\": 850.0,\n \"target_price_12m\": 700.0,\n \"recommendation\": \"SELL\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\"High P/E suggests overvaluation vs earnings growth.\", \"Revenue decline challenges top-line expansion.\", \"Low operating margins limit profit improvements.\", \"Defensive sector offers stability but low upside.\", \"Forward P/E indicates expected earnings catch-up.\"],\n \"key_drivers\": [\n { \"driver\": \"Healthcare regulatory changes\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Drug pricing pressure\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Operational efficiency gains\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Technological investments in supply chain\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n { \"driver\": \"Economic sensitivity\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Competitive landscape intensification\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Acquisition opportunities\", \"impact\": \"LOW\", \"direction\": \"POS\" }\n ],\n \"risks\": [\"Regulatory changes affecting distribution margins\", \"Supply chain disruptions increasing costs\", \"Cybersecurity threats to healthcare data\", \"Dependence on key pharmaceutical suppliers\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 1.0,\n \"ebit_margin_target\": 1.8,\n \"wacc\": 7.0,\n \"terminal_multiple\": 16.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 600.0, \"prob\": 0.3, \"notes\": \"Further revenue decline and margin pressure.\" },\n \"base\": { \"target_price\": 700.0, \"prob\": 0.5, \"notes\": \"Modest growth with stable margins.\" },\n \"bull\": { \"target_price\": 800.0, \"prob\": 0.2, \"notes\": \"Efficiency gains and slight revenue growth.\" }\n },\n \"method_notes\": \"EV/EBITDA-based DCF with low growth assumptions. Current price overvalued vs. fundamentals. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI_Equity_Model", "risks": [ "Regulatory changes affecting distribution margins", "Supply chain disruptions increasing costs", "Cybersecurity threats to healthcare data", "Dependence on key pharmaceutical suppliers" ], "ticker": "MCK", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Modest growth with stable margins.", "target_price": 700 }, "bear": { "prob": 0.3, "notes": "Further revenue decline and margin pressure.", "target_price": 600 }, "bull": { "prob": 0.2, "notes": "Efficiency gains and slight revenue growth.", "target_price": 800 } }, "confidence": 0.6, "assumptions": { "wacc": 7, "revenue_cagr_3y": 1, "terminal_multiple": 16, "ebit_margin_target": 1.8 }, "key_drivers": [ { "driver": "Healthcare regulatory changes", "impact": "MED", "direction": "NEG" }, { "driver": "Drug pricing pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Operational efficiency gains", "impact": "MED", "direction": "POS" }, { "driver": "Technological investments in supply chain", "impact": "LOW", "direction": "POS" }, { "driver": "Economic sensitivity", "impact": "LOW", "direction": "NEG" }, { "driver": "Competitive landscape intensification", "impact": "MED", "direction": "NEG" }, { "driver": "Acquisition opportunities", "impact": "LOW", "direction": "POS" } ], "method_notes": "EV/EBITDA-based DCF with low growth assumptions. Current price overvalued vs. fundamentals. Not investment advice.", "current_price": 871.18, "recommendation": "SELL", "thesis_bullets": [ "High P/E suggests overvaluation vs earnings growth.", "Revenue decline challenges top-line expansion.", "Low operating margins limit profit improvements.", "Defensive sector offers stability but low upside.", "Forward P/E indicates expected earnings catch-up." ], "target_price_6m": 850, "target_price_12m": 700 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 383, "createdAt": "2026-04-09T05:21:22.865Z", "usage": { "inputTokens": 2176, "outputTokens": 4406, "costUsd": 0.00246 } }, { "id": "cmnr14k3a050up658wmvgmuam", "runId": "cmnr14k37050rp658vtrkq09q", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\"model\":\"Equity Research AI\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MCK\",\"currency\":\"USD\",\"current_price\":871.18,\"target_price_6m\":920.0,\"target_price_12m\":965.0,\"recommendation\":\"BUY\",\"confidence\":0.7,\"thesis_bullets\":[\"Market leadership in drug distribution provides a wide economic moat and stable cash flows.\",\"Shift toward high-margin specialty pharmacy and oncology services improves overall profitability profile.\",\"Strong free cash flow generation supports consistent share repurchases and dividend growth.\",\"Increased utilization of GLP-1 medications and specialty biologics drives significant volume growth.\",\"Current valuation provides an attractive entry point relative to long-term earnings power.\"],\"key_drivers\":[{\"driver\":\"Specialty pharmacy mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"GLP-1 drug demand\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Share repurchase execution\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Drug pricing legislation\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Generic price deflation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Oncology network scale\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Regulatory changes impacting PBM and wholesaler reimbursement models.\",\"Concentration risk with major retail pharmacy customers like CVS.\",\"Potential for increased competition in the specialty distribution space.\"],\"assumptions\":{\"revenue_cagr_3y\":5.5,\"ebit_margin_target\":1.6,\"wacc\":7.8,\"terminal_multiple\":16.0},\"scenarios\":{\"bear\":{\"target_price\":740.0,\"prob\":0.2,\"notes\":\"Regulatory headwinds and margin compression in generics.\"},\"base\":{\"target_price\":965.0,\"prob\":0.55,\"notes\":\"Steady growth in specialty pharmacy and oncology.\"},\"bull\":{\"target_price\":1100.0,\"prob\":0.25,\"notes\":\"Accelerated buybacks and higher GLP-1 distribution margins.\"}},\"method_notes\":\"Valuation utilizes a 17.5x forward P/E multiple applied to projected FY27 earnings. Target reflects 11% upside plus dividend. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Equity Research AI", "risks": [ "Regulatory changes impacting PBM and wholesaler reimbursement models.", "Concentration risk with major retail pharmacy customers like CVS.", "Potential for increased competition in the specialty distribution space." ], "ticker": "MCK", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady growth in specialty pharmacy and oncology.", "target_price": 965 }, "bear": { "prob": 0.2, "notes": "Regulatory headwinds and margin compression in generics.", "target_price": 740 }, "bull": { "prob": 0.25, "notes": "Accelerated buybacks and higher GLP-1 distribution margins.", "target_price": 1100 } }, "confidence": 0.7, "assumptions": { "wacc": 7.8, "revenue_cagr_3y": 5.5, "terminal_multiple": 16, "ebit_margin_target": 1.6 }, "key_drivers": [ { "driver": "Specialty pharmacy mix", "impact": "HIGH", "direction": "POS" }, { "driver": "GLP-1 drug demand", "impact": "MED", "direction": "POS" }, { "driver": "Share repurchase execution", "impact": "MED", "direction": "POS" }, { "driver": "Drug pricing legislation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Generic price deflation", "impact": "MED", "direction": "NEG" }, { "driver": "Oncology network scale", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation utilizes a 17.5x forward P/E multiple applied to projected FY27 earnings. Target reflects 11% upside plus dividend. Not investment advice.", "current_price": 871.18, "recommendation": "BUY", "thesis_bullets": [ "Market leadership in drug distribution provides a wide economic moat and stable cash flows.", "Shift toward high-margin specialty pharmacy and oncology services improves overall profitability profile.", "Strong free cash flow generation supports consistent share repurchases and dividend growth.", "Increased utilization of GLP-1 medications and specialty biologics drives significant volume growth.", "Current valuation provides an attractive entry point relative to long-term earnings power." ], "target_price_6m": 920, "target_price_12m": 965 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-flash-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 17619, "createdAt": "2026-04-09T05:21:22.865Z", "usage": { "inputTokens": 2542, "outputTokens": 494, "costUsd": 0.011012 } }, { "id": "cmnr14k3a050sp658rzeks13m", "runId": "cmnr14k37050rp658vtrkq09q", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MCK\",\"currency\":\"USD\",\"current_price\":871.18,\"target_price_6m\":915,\"target_price_12m\":950,\"recommendation\":\"BUY\",\"confidence\":0.64,\"thesis_bullets\":[\"Scale and essential distribution support resilient cash generation across healthcare cycles.\",\"Forward P/E is reasonable versus mid-teens EPS growth and steady buybacks.\",\"Specialty, oncology, and biopharma services should improve mix and earnings durability.\",\"Very thin margins cap upside if volume, pricing, or contracts weaken.\",\"Defensive quality merits some premium, but upside remains moderate rather than outsized.\"],\"key_drivers\":[{\"driver\":\"Pharma distribution volume\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Specialty and oncology mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Share repurchases\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Biopharma services growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Forward P/E normalization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Generic price deflation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Thin operating margins\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Customer contract pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Generic deflation or reimbursement pressure\",\"Large customer contract repricing or loss\",\"Working-capital volatility and low liquidity ratios\",\"Regulatory or litigation costs\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.017,\"wacc\":0.075,\"terminal_multiple\":18},\"scenarios\":{\"bear\":{\"target_price\":780,\"prob\":0.2,\"notes\":\"Contract pressure and deflation compress earnings and valuation.\"},\"base\":{\"target_price\":950,\"prob\":0.55,\"notes\":\"Steady volumes, mix gains, and buybacks drive moderate appreciation.\"},\"bull\":{\"target_price\":1070,\"prob\":0.25,\"notes\":\"Specialty momentum and strong execution sustain faster EPS growth.\"}},\"method_notes\":\"Hybrid valuation using normalized forward earnings multiple cross-checked with FCF durability; snapshot quote/fundamentals kept authoritative. BUY fits ~9% 12M base upside and ~7% probability-weighted upside. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation", "risks": [ "Generic deflation or reimbursement pressure", "Large customer contract repricing or loss", "Working-capital volatility and low liquidity ratios", "Regulatory or litigation costs" ], "ticker": "MCK", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady volumes, mix gains, and buybacks drive moderate appreciation.", "target_price": 950 }, "bear": { "prob": 0.2, "notes": "Contract pressure and deflation compress earnings and valuation.", "target_price": 780 }, "bull": { "prob": 0.25, "notes": "Specialty momentum and strong execution sustain faster EPS growth.", "target_price": 1070 } }, "confidence": 0.64, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.05, "terminal_multiple": 18, "ebit_margin_target": 0.017 }, "key_drivers": [ { "driver": "Pharma distribution volume", "impact": "HIGH", "direction": "POS" }, { "driver": "Specialty and oncology mix", "impact": "HIGH", "direction": "POS" }, { "driver": "Share repurchases", "impact": "HIGH", "direction": "POS" }, { "driver": "Biopharma services growth", "impact": "MED", "direction": "POS" }, { "driver": "Forward P/E normalization", "impact": "MED", "direction": "POS" }, { "driver": "Generic price deflation", "impact": "MED", "direction": "NEG" }, { "driver": "Thin operating margins", "impact": "HIGH", "direction": "NEG" }, { "driver": "Customer contract pressure", "impact": "MED", "direction": "NEG" } ], "method_notes": "Hybrid valuation using normalized forward earnings multiple cross-checked with FCF durability; snapshot quote/fundamentals kept authoritative. BUY fits ~9% 12M base upside and ~7% probability-weighted upside. not investment advice", "current_price": 871.18, "recommendation": "BUY", "thesis_bullets": [ "Scale and essential distribution support resilient cash generation across healthcare cycles.", "Forward P/E is reasonable versus mid-teens EPS growth and steady buybacks.", "Specialty, oncology, and biopharma services should improve mix and earnings durability.", "Very thin margins cap upside if volume, pricing, or contracts weaken.", "Defensive quality merits some premium, but upside remains moderate rather than outsized." ], "target_price_6m": 915, "target_price_12m": 950 }, "errorsJson": { "attempts": [ { "error": "sanity_error: buy_scenario_return_too_low: BUY requires >= 6% return from probability-weighted scenarios.", "attempt": 0, "rawOutputTruncated": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MCK\",\"currency\":\"USD\",\"current_price\":871.18,\"target_price_6m\":905,\"target_price_12m\":940,\"recommendation\":\"BUY\",\"confidence\":0.63,\"thesis_bullets\":[\"Scale and essential distribution support resilient cash flow through healthcare cycles.\",\"Forward valuation looks reasonable against mid-teens EPS growth and buybacks.\",\"Specialty, oncology, and biopharma services should lift mix and earnings durability.\",\"Margins remain structurally thin, limiting upside if volume or pricing normalizes.\",\"At current levels, upside is modest but favorable for defensive compounding.\"],\"key_drivers\":[{\"driver\":\"Pharma distribution volume\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Specialty and oncology mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Share repurchases\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Biopharma services expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Generic price deflation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Thin operating margins\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Customer concentration\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory/legal overhang\"…" } ], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0063849d224cc1c60069d75b544b2c8190ae5200e8af3e2fa4", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 13809, "createdAt": "2026-04-09T05:21:22.865Z", "usage": { "inputTokens": 2958, "outputTokens": 873, "costUsd": 0.017399 } }, { "id": "cmnr14k3a050vp658wpgmc633", "runId": "cmnr14k37050rp658vtrkq09q", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Recommendation Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"MCK\",\n \"currency\": \"USD\",\n \"current_price\": 871.18,\n \"target_price_6m\": 915,\n \"target_price_12m\": 950,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Stable pharma distribution demand supports revenue.\",\n \"Specialty drugs and oncology drive margin gains.\",\n \"Strong FCF funds buybacks and dividend growth.\",\n \"Low beta offers defensive healthcare exposure.\",\n \"Forward valuation reasonable versus growth outlook.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Aging population chronic care demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Specialty pharmaceutical distribution\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Drug pricing reform legislation\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operational efficiency programs\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Supplier and customer consolidation\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Supply chain and logistics costs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Health IT and data analytics\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Interest rate impact on valuation\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Drug pricing legislation pressure\",\n \"Opioid litigation outcomes\",\n \"Cybersecurity and data breaches\",\n \"Supply chain disruptions\",\n \"Customer concentration risk\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.017,\n \"wacc\": 0.09,\n \"terminal_multiple\": 15\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 720,\n \"prob\": 0.25,\n \"notes\": \"Regulatory margin compression and de-rating.\"\n },\n \"base\": {\n \"target_price\": 950,\n \"prob\": 0.5,\n \"notes\": \"Steady execution on distribution growth.\"\n },\n \"bull\": {\n \"target_price\": 1080,\n \"prob\": 0.25,\n \"notes\": \"Accelerated oncology growth and efficiencies.\"\n }\n },\n \"method_notes\": \"DCF using 5% rev CAGR, 1.7% EBIT margin, 9% WACC, 15x terminal. 9% 12M upside supports BUY. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Recommendation Model", "risks": [ "Drug pricing legislation pressure", "Opioid litigation outcomes", "Cybersecurity and data breaches", "Supply chain disruptions", "Customer concentration risk" ], "ticker": "MCK", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution on distribution growth.", "target_price": 950 }, "bear": { "prob": 0.25, "notes": "Regulatory margin compression and de-rating.", "target_price": 720 }, "bull": { "prob": 0.25, "notes": "Accelerated oncology growth and efficiencies.", "target_price": 1080 } }, "confidence": 0.62, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.05, "terminal_multiple": 15, "ebit_margin_target": 0.017 }, "key_drivers": [ { "driver": "Aging population chronic care demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Specialty pharmaceutical distribution", "impact": "HIGH", "direction": "POS" }, { "driver": "Drug pricing reform legislation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Operational efficiency programs", "impact": "MED", "direction": "POS" }, { "driver": "Supplier and customer consolidation", "impact": "MED", "direction": "NEG" }, { "driver": "Supply chain and logistics costs", "impact": "MED", "direction": "NEG" }, { "driver": "Health IT and data analytics", "impact": "MED", "direction": "POS" }, { "driver": "Interest rate impact on valuation", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF using 5% rev CAGR, 1.7% EBIT margin, 9% WACC, 15x terminal. 9% 12M upside supports BUY. not investment advice.", "current_price": 871.18, "recommendation": "BUY", "thesis_bullets": [ "Stable pharma distribution demand supports revenue.", "Specialty drugs and oncology drive margin gains.", "Strong FCF funds buybacks and dividend growth.", "Low beta offers defensive healthcare exposure.", "Forward valuation reasonable versus growth outlook." ], "target_price_6m": 915, "target_price_12m": 950 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "bd49e5cf-6fb6-9ae1-950b-a17daef62653", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 17487, "createdAt": "2026-04-09T05:21:22.865Z", "usage": { "inputTokens": 2783, "outputTokens": 2527, "costUsd": 0.046254 } } ] } }